The Jak-Stat pathway in normal and perturbed hematopoiesis

Blood

Volumn 95, Issue 1, 2000, Pages 19-29

  Ward, Alister C ^a   Touw, Ivo ^b   Yoshimura, Akihiko ^b  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATASE; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; BLOOD DISEASE; CELL MATURATION; COMBINED IMMUNODEFICIENCY; ENZYME ANALYSIS; ERYTHROCYTOSIS; FANCONI ANEMIA; GENE INDUCTION; HEMATOPOIESIS; HUMAN; MODEL; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW;

EID: 0033976059     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.1.19.001k34_19_29     Document Type: Review

References (199)

1. Taniguchi T. Cytokine signaling through nonreceptor protein tyrosine kinases. Science. 1995; 268:251-255.
2. Ihle JN. Signaling by the cytokine receptor superfamily in normal and transformed hematopoietic cells. Adv Cancer Res. 1996;68:23-65.
3. Wells JA, de Vos AM. Hematopoietic receptor complexes. Annu Rev Biochem. 1996;65:609-634.
4. Cacalano NA, Migone TS, Bazan F, et al. Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain. EMBO J. 1999;18:1549-1558.
5. Novak U, Harpur AG, Paradiso L, et al. CSF-1 induced STAT activation is accompanied by phosphorylation of Tyk2 in macrophages and Tyk2 and JAK1 in fibroblasts. Blood. 1995;86:2948-2956
6. Deberry C, Mou S, Linnekin D. Stat1 associates with c-kit and is activated in response to stem cell factor. Biochem J. 1997;327:73-80.
7. Müller M, Briscoe J, Laxton C, et al. The protein tyrosine kinase JAK1 complements defects in interferon-α/β and -γ signal transduction. Nature. 1993;366:129-135.
8. Watling D, Guschin D, Muller M, et al. Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in interferon-gamma signal transduction. Nature. 1993;366:166-170.
9. Velazquez L, Fellous M, Stark GR, Pellegrini S. A protein tyrosine kinase in the interferon alpha/ beta signaling pathway. Cell. 1992;70:313-322.
10. Miura O, Cleveland JL, Ihle JN. Inactivation of erythropoietin receptor function by point mutations in a region having homology with other cytokine receptors. Mol Cell Biol. 1993;13:1788-1795.
11. c chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region. Mol Cell Biol. 1994;14:4335-4341.
12. Zhuang H, Niu Z, He TC, Patel SV, Wojchowski DM. Erythropoietin-dependent inhibition of apoptosis is supported by carboxyl-truncated receptor forms and blocked by dominant-negative forms of Jak2. J Biol Chem. 1995;270:14500-14504.
13. Barge RM, de Koning JP, Pouwels K, Dong F, Löwenberg B, Touw IP. Tryptophan 650 of human granulocyte colony-stimulating factor (G-CSF) receptor, implicated in the activation of JAK2, is also required for G-CSF-mediated activation of signaling complexes of the p21ras route. Blood. 1996;87:2148-2153.
14. Nicholson SE, Willson TA, Farley A, et al. Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibtion of LIF and IL-6 signal transduction. EMBO J. 1999;18:375-385.
15. Rodig SJ, Meraz MA, White JM, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell. 1998;93:373-383.
16. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 1998;93:385-395.
17. Neubauer H, Cumano A, Muller M, Wu H, Huffstadt U, Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell. 1998;93:397-409.
18. Nosaka T, van Deursen JM, Tripp RA, et al. Defective lymphoid development in mice lacking Jak3. Science. 1995;270:800-802.
19. Park SY, Saijo K, Takahashi T, et al. Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity. 1995;3:771-782.
20. Grossman WJ, Verbsky JW, Yang L, et al. Dysregulated myelopoiesis in mice lacking Jak3. Blood. 1999;94:932-939.
21. Darnell JE Jr. STATs and gene regulation. Science. 1997;277:1630-1635.
22. Meraz MA, White JM, Sheehan KCF, et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell. 1996;84:431-442.
23. Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell. 1996;85:443-450.
24. Takeda K, Noguchi K, Shi W, et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A. 1997;94:3801-3804.
25. Takeda K, Kaisho T, Yoshida N, Takeda J, Kishimoto T, Akira S. Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J Immunol. 1998;161:4652-4660.
26. Thierfelder WE, Van Deursen J, Yamamoto K, et al. Requirement for Stat4 in interleukin-12 mediated responses of natural killer cells. Nature. 1996;382:171-174.
27. Kaplan MH, Sun YL, Hoey T, Grusby MJ. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature. 1996;382:174-177.
28. Teglund S, McKay C, Schuetz E, et al. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell. 1998;93:841-850.
29. Moriggl R, Topham DJ, Teglund S, et al. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity. 1999;10:249-259.
30. Feldman GM, Rosenthal LA, Liu X, et al. STAT5A-deficient mice demonstrate a defect in granulocyte-macrophage colony-stimulating factor-induced proliferation and gene expression. Blood. 1997;90:1768-1776.
31. Imada K, Bloom ET, Nakajima H, et al. Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity. J Exp Med. 1998;188: 2067-2074.
32. Takeda K, Tanaka T, Shi W, et al. Essential role of Stat6 in IL-4 signalling. Nature. 1996;380:627-630.
33. Shimoda K, van Deursen J, Sangster MY, et al. Lack of IL-4 induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature. 1996;380:630-633.
34. Müller M, Laxton C, Briscoe J, et al. Complementation of a mutant cell line: central role of the 91 kDa polypeptide of ISGF3 in the interferon-α and -γ signal transduction pathways. EMBO J. 1993; 12:4221-4228.
35. Nakajima K, Yamanaka Y, Nakae K, et al. A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J. 1996;15:3651-3658.
36. Shimozaki K, Nakajima K, Hirano T, Nagata S. Involvement of STAT3 in the granulocyte colony-stimulating factor-induced differentiation of myeloid cells. J Biol Chem. 1997;272:25,184-25, 189.
37. Ward AC, Smith L, de Koning JP, van Aesch Y, Touw IP. Multiple signals mediate proliferation, differentiation and survival from the granulocyte colony-stimulating factor receptor in myeloid 32D cells. J Biol Chem. 1999;274:14,956-14,962.
38. Mui AL-F, Wakao H, O'Farrell A-M, Harada N, Miyajima A. Interleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 transduce signals through two STAT5 homologs. EMBO J. 1995;14:1166-1175.
39. Dong F, Liu X, de Koning JP, et al. Stimulation of Stat5 by granulocyte colony-stimulating factor (G-CSF) is modulated by two distinct cytoplasmic regions of the G-CSF receptor. J Immunol. 1998; 161:6503-6509.
40. Ilaria RL Jr, Hawley RG, Van Etten RA. Dominant negative mutants implicate STAT5 in myeloid cell proliferation and neutrophil differentiation. Blood. 1999;93:4154-4166.
41. Horvath CM, Darnell JE Jr. The state of the STATs: recent developments in the study of signal transduction to the nucleus. Curr Opin Cell Biol. 1997;9:233-239.
42. Darnell JE Jr, Kerr IM, Stark GR. JAK-STAT pathways and transcriptional activation in response to interferons and other extracellular signalling proteins. Science. 1994;264:1415-1421.
43. O'Shea JJ. Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet? Immunity. 1997;7:1-11.
44. Schindler C, Damell JE Jr. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem. 1995;64:621-651.
45. Ward AC, Hermans MHA, Smith L, et al. Tyrosine-dependent and independent mechanisms of STAT3 activation by the human granulocyte colony-stimulating factor (G-CSF) receptor are differentially utilized depending on G-CSF concentration. Blood. 1999;93:113-124.
46. Ward AC, van Aesch YM, Schelen AM, Touw IP. Defective internalization and sustained activation of truncated granulocyte colony-stimulating factor receptor found in severe congenital neutropenia/ acute myeloid leukemia. Blood. 1999;93:447-458.
47. Ihle JN, Kerr IM. Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet. 1995;11:69-74.
48. Heim MH, Kerr IM, Stark GR, Darnell JE Jr. Contribution of STAT SH2 groups to specific interferon signaling by the Jak-STAT pathway. Science. 1995;267:1347-1349.
49. Hou J, Schindler U, Henzel WJ, Ho TC, Brasseur M, McKnight SL. An interleukin-4-induced transcription factor: IL-4 Stat. Science. 1994;265: 1701-1706.
50. Stahl N, Farruggella TJ, Bolton TG, Zhong Z, Darnell JE, Yancopoulos GD. Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science. 1995;267:1349-1353.
51. de Koning JP, Dong F, Smith L, et al. The membrane-distal cytoplasmic region of human granulocyte colony-stimulating factor receptor is required for STAT3 but not STAT1 homodimer formation. Blood. 1996;87:1335-1342.
52. Wang YD, Wong K, Wood WI. Intracellular tyrosine residues of the human growth hormone receptor are not required for the signaling of proliferation or Jak-STAT activation. J Biol Chem. 1995;270:7021-7024.
53. Shuai K, Stark GR, Kerr I, Darnell JE Jr. A single phosphotyrosine residue of Stat91 required for gene activation by interferon-γ. Science. 1993; 261:1744-1746.
54. Wakao H, Gouilleux F, Groner B. Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. EMBO J. 1994; 13:2182-2191.
55. Shimoda K, Feng J, Murakami H, et al. Jak1 plays an essential role for receptor phosphorylation and Stat activation in response to granulocyte colony-stimulating factor. Blood. 1997;90: 597-604.
56. Avalos BR, Parker JM, Ware DA, Hunter MG, Sibert KA, Druker BJ. Dissociation of the Jak kinase pathway from G-CSF receptor signaling in neutrophils. Exp Hematol. 1997;25:160-168.
57. Caldenhoven E, van Dijk TB, Raaijmakers JAM, Lammers J-WJ, Koenderman L, de Groot RP. Activation of a functionally distinct 80-kDa STAT5 isoform by IL-5 and GM-CSF in human eosinophils and neutrophils. Mol Cell Biol Res Comm. 1999;1:95-101.
58. Caldenhoven E, Buitenhuis M, van Dijk TB, et al. Lineage-specific activation of STAT3 by interferon-gamma in human neutrophils. J Leukoc Biol. 1999;65:391-396.
59. Castro A, Sengupta TK, Ruiz DC, Yang E, Ivashkiv LB. IL-4 selectively inhibits IL-2-triggered Stat5 activation, but not proliferation, in human T cells. J Immunol. 1999;162:1261-1269.
60. Ito S, Ansari P, Sakatsume M, et al. Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma-induced genes by suppressing tyrosine phosphorylation of STAT1. Blood. 1999; 93:1456-1463.
61. 2 and other cyclic adenosine monophosphate-elevating agents: impact on interleukin-2 receptor signaling pathway. Blood. 1999;93:2308-2318.
62. Lamb P, Seidel HM, Haslam J, et al. STAT protein complexes activated by interferon-γ and gp130 signaling molecules differ in their sequence preferences and transcriptional induction properties. Nucl Acids Res. 1995;23:3283-3289.
63. Seidel HM, Milocco LH, Lamb P, Damell JE Jr, Stein RB, Rosen J. Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity. Proc Natl Acad Sci U S A. 1995;92:3041-3045.
64. Decker T, Kovarik P, Meinke A. GAS elements: a few nucleotides with a major impact on cytokine-induced gene expression. J Interferon Cytokine Res. 1997;17:121-134.
65. Caldenhoven E, van Dijk TB, Solari R, et al. STAT3 beta, a splice variant of transcription factor STAT3, is a dominant-negative regulator of transcription. J Biol Chem. 1996;271:13,221-13,227.
66. Luo G, Yu-Lee L. Transcriptional inhibition by Stat5: differential activities at growth-related versus differentiation-specific promoters. J Biol Chem. 1997;272:26,841-26,849.
67. Schaefer TS, Sanders LK, Nathans D. Cooperative transcriptional activity of Jun and Stat3 beta, a short form of Stat3. Proc Natl Acad Sci U S A. 1995;92:9097-9101.
68. Zhang JJ, Zhao Y, Chait BT, et al. Ser727-dependent recruitment of MCM5 by Stat1α in IFN-γ-induced transcriptional activation. EMBO J. 1998; 17:6963-6971.
69. Zhu M-H, John S, Berg M, Leonard WJ. Functional association of Nmi with Stat5 and Stat1 in IL-2- and IFNγ-mediated signaling. Cell. 1999;96: 121-130.
70. Wen Z, Zhong Z, Darnell JE Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell. 1995;82:241-250.
71. Zhang X, Blenis J, Li H-C, Schindler C, Chen-Kiang S. Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science. 1995;267:1990-1994.
72. Chung CD, Liao J, Liu B, et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science. 1997;278:1803-1805.
73. Jain N, Zhang T, Fong SL, Lim CP, Cao X. Repression of Stat3 activity by activation of mitogen-activated protein kinase. Oncogene. 1998;17: 3157-3167.
74. Miyazaki T, Takaoka A, Nogueira L, et al. Pyk2 is a downstream mediator of the IL-2 receptor-coupled Jak signaling pathway. Genes Dev. 1998; 12:770-775.
75. Schiemann WP, Bartoe JL, Nathanson NM. Box 3-independent signaling mechanisms are involved in leukemia inhibitory factor receptor alpha- and gp130-mediated stimulation of mitogen-activated protein kinase: evidence for participation of multiple signaling pathways which converge at Ras. J Biol Chem. 1997;272:16,631-16,636.
76. Mizuguchi R, Hatakeyama M. Conditional activation of Janus kinase (JAK) confers factor independence upon interleukin-3-dependent cells: essential role of Ras in JAK-triggered mitogenesis. J Biol Chem. 1998;273:32,297-32,303.
77. Watanabe S, Itoh T, Arai K. Roles of JAK kinase in human GM-CSF receptor signals. Leukemia. 1997;11(suppl3):76-78.
78. Karras JG, Wang Z, Huo L, Frank DA, Rothstein TL. Induction of STAT protein signaling through the CD40 receptor in B lymphocytes: distinct STAT activation following surface Ig and CD40 receptor engagement. J Immunol. 1997;159: 4350-4355.
79. Cao X, Tay A, Guy GR, Tan YH. Activation and association of Stat3 with Src in v-Src-transformed cell lines. Mol Cell Biol. 1996;16:1595-1603.
80. Rhodes J, York RD, Tajinda K, Tara D, Druker BJ. Analysis of CrkL and Stat5 interactions in Bcr-Abl-expressing cells [abstract]. Blood. 1998;92: 476a.
81. Yamashita H, Xu J, Erwin RA, Farrar WL, Kirken RA, Rui H. Differential control of the phosphorylation state of proline-juxtaposed serine residues Ser725 of Stat5a and Ser730 of Stat5b in prolactin-sensitive cells. J Biol Chem. 1998;273:30218-30224.
82. Kim TK, Maniatis T. Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway. Science. 1996;273:1717-1719.
83. Strous GJ, van Kerkhof P, Covers R, Ciechanover A, Schwartz AL. The ubiquitin conjugation system is required for ligand-induced endocytosis and degradation of the growth hormone receptor. EMBO J. 1996;15:3806-3812.
84. Wang D, Stravopodis D, Teglund S, Kitazawa J, Ihle JN. Naturally occurring dominant negative variants of Stat5. Mol Cell Biol. 1996;16:6141-6148.
85. Azam M, Lee C, Strethlow I, Schindler C. Functionally distinct isoforms of STAT5 are generated by protein processing. Immunity. 1997;6:691-701.
86. Liu B, Liao J, Rao X, et al. Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci U S A. 1998;95:10,626-10,631.
87. Masuhara M, Sakamoto H, Matsumoto A, et al. Cloning and characterization of novel CIS family genes. Biochem Biophys Res Comm. 1997;239: 439-446.
88. Hilton DJ, Richardson RT, Alexander WS, et al. Twenty proteins containing a C-terminal SOCS box form live structural classes. Proc Natl Acad Sci U S A. 1998;95:114-119.
89. Yoshimura A. The CIS family: negative regulators of JAK-STAT signaling. Cytokine Growth Factor Rev. 1998;9:197-204.
90. Yoshimura A, Ohkubo T, Kiguchi T, et al. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J. 1995;14:2816-2826.
91. Uchida K, Yoshimura A, Inazawa J, et al. Molecular cloning of CISH, chromosomal assignment to 3p21.3, and analysis of expression in fetal and adult tissues. Cytogenet Cell Genet. 1997;78:209-212.
92. Matsumoto A, Masuhara M, Mitsui K, et al. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood. 1997;89:3148-3154.
93. Verdier F, Chretien S, Muller O, et al. Proteasomes regulate erythropoietin receptor and STAT5 activation: possible involvement of the ubiquitinated CIS protein. J Biol Chem. 1998;273: 28,185-28,190.
94. Matsumoto A, Seki Y, Kubo M, et al. Suppression of STAT5 functions in liver, mammary glands, and T cells in cytokine-inducible SH2 protein-1 (CIS1) transgenic mice. Mol Cell Biol. 1999;19:6396-6407.
95. Endo TA, Masuhara M, Yokouchi M. et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature. 1997;387:921-924.
96. Ohya KI, Kajigaya S, Yamashita Y, et al. SOCS-1/ JAB/SSI-1 can bind to and suppress Tec protein-tyrosine kinase. J Biol Chem. 1997;272:27178-27182.
97. Starr R, Wilson TA, Viney EM, et al. A family of cytokine-inducible inhibitors of signalling. Nature. 1997;387:917-921.
98. Naka T, Narazaki M, Hirata M, et al. Structure and function of a new STAT-induced STAT inhibitor. Nature. 1997;387:924-929.
99. De Sepulveda P, Okkenhaug K, Rose JL, Hawley RG, Dubreuil P, Rottapel R. Socs1 binds to multiple signalling proteins and suppresses Steel factor-dependent proliferation. EMBO J. 1999;18: 904-915.
100. Naka T, Matsumoto T, Narazaki M, et al. Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STAT inhibitor-1) deficient mice. Proc Natl Acad Sci U S A. 1998;95:15,577-15,582.
101. Starr R, Metcalf D, Elefanty AG, et al. Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. Proc Natl Acad Sci U S A. 1998;95:14,395-14,399.
102. Young HA, Klinman DM, Reynolds DA, et al. Bone marrow and thymus expression of interferon-gamma results in severe B-cell lineage reduction, T-cell lineage alterations, and hematopoietic progenitor deficiencies. Blood. 1997;89: 583-595.
103. Metcalf D, Alexander WS, Elefanty AG, et al. Aberrant hematopoiesis in mice with inactivation of the gene encoding SOCS-1. Leukemia. 1999;13: 926-934.
104. Nicola NA, Nicholson S, Metcalf D, et al. Negative regulation of cytokine signaling by SOCS proteins [abstract]. LXIV Cold Spring Harbor Symposium on Quantitative Biology. 1999:237a.
105. Yasukawa H, Misawa H, Sakamoto H, et al. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J. 1999;18:1309-1320.
106. Liu KD, Gaffen SL, Goldsmith MA, Greene WC. Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation. Curr Biol.1997;7:817-826.
107. Weiss A, Schlessinger J. Switching signals on or off by receptor dimerization Cell. 1998;94:277-280.
108. Kamura T, Sato S, Haque D, et al. The elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev. 1998;12:3872-3881.
109. Zhang J-G, Farley A, Nicholson SE, et al. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc Natl Acad Sci U S A. 1999;96: 2071-2076.
110. Tyers M, Willems AR. One ring to rule a superfamily of E3 ubiquitin ligases. Science. 1999;284: 603-604.
111. Narazaki M, Fujimoto M, Matsumoto T, et al. Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling. Proc Natl Acad Sci U S A. 1998;95:13,130-13,134.
112. Klingmüller U, Lorenz U, Cantley LC, Neel BG, Lodish HF. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell. 1995;80:729-738.
113. Fuhrer DK, Feng G-S, Yang Y-C. Syp associates with gp130 and Janus Kinase 2 in response to interleukin-11 in 3T3-L1 mouse preadipocytes. J Biol Chem. 1995;270:24,826-24,830.
114. Jiao H, Berrada K, Yang W, Tabrizi M, Platanias LC, Yi T. Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1. Mol Cell Biol. 1996;16:6985-6992.
115. You M, Yu D-H, Feng G-S. Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak-STAT pathway. Mol Cell Biol. 1999;19:2416-2424.
116. Carpenter LR, Farruggella TJ, Symes A, Karow ML, Yancopoulos GD, Stahl N. Enhancing leptin responses by preventing SH2-containing phosphatase 2 interaction with Ob receptor. Proc Natl Acad Sci U S A. 1998;95:6061-6066.
117. Shultz LD, Schweitzer PA, Rajan TV, et al. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell. 1993;73:1445-1454.
118. Plas DR, Johnson R, Pingel JT, et al. Direct regulation of ZAP-70 by SHP-1 in T cell antigen receptor signaling. Science. 1996;272:1173-1176.
119. Kozlowski M, Larose L, Lee F, Le DM, Rottapel R, Siminovitch KA. SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain. Mol Cell Biol. 1998;18:2089-2099.
120. Ram PA, Waxman DJ. Interaction of growth hormone-activated STATs with SH2-containing phosphotyrosine phosphatase SHP-1 and nuclear JAK2 tyrosine kinase. J Biol Chem. 1997;272: 17,694-17,702.
121. Lacronique V, Boureux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 1997;278:1309-1312.
122. Peeters P, Raynaud SD, Cools J, et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9; 12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood. 1997;90:2535-2540.
123. Schwaller J, Frantsve J, Aster J, et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J. 1998;17:5321-5333.
124. Ho JM-Y, Beattie BK, Squire JA, Frank DA, Barber DL. Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling. Blood. 1999;93:4354-4364.
125. Garcia R, Jove R. Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. J Biomed Sci. 1998;5:79-85.
126. Harrison DA, Binari R, Nahreini TS, Gilman M, Perrimon N. Activation of a Drosophila Janus kinase (JAK) causes hematopoietic neoplasia and developmental defects. EMBO J. 1995;14:2857-2865.
127. Luo H, Rose P, Barber D, et al. Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways. Mol Cell Biol. 1997;17:1562-1571.
128. Meydan N, Grunberger T, Dadi H, et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature. 1996;379:645-648.
129. Ilaria RL Jr, Van Etten RA. P210 and P190 (BCR/ ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem. 1996;271:31,704-31,710.
130. Chaturvedi P, Sharma S, Reddy EP. Abrogation of interleukin-3 dependence of myeloid cells by the v-src oncogene requires SH2 and SH3 domains which specify activation of STATs. Mol Cell Biol. 1997;17:3295-3304.
131. Lund TC, Prator PC, Medveczky MM, Medveczky PG. The Lck binding domain of herpesvirus saimiri tip-484 constitutively activates Lck and STAT3 in T cells. J Virol. 1999;73:1689-1694.
132. Nieborowska-Skorska M, Wasik MA, Slupianek A, et al. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Srh homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med. 1999;189:1229-1242.
133. de Groot RP, Raaijmakers JAM, Lammers J-WJ, Jove R, Koenderman L. STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. Blood. 1999;94:1108-1112.
134. Turkson J, Bowman T, Garcia R, Caldenhoven E, de Groot RP, Jove R. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol. 1998;18:2545-2552.
135. Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell JE Jr. Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol. 1998;18:2553-2558.
136. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10:105-115.
137. Onishi M, Nosaka T, Misawa K, et al. Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol Cell Biol. 1998;18:3871-3879.
138. Sakai I, Kraft AS. The kinase domain of Jak2 mediates induction of bcl-2 and delays cell death in hematopoietic cells. J Biol Chem. 1997;272: 12,350-12,358.
139. Voss SD, Hong R, Sondel PM. Severe combined immunodeficiency, interleukin-2 (IL-2), and the IL-2 receptor: experiments of nature continue to point the way. Blood. 1994;83:626-635.
140. Noguchi M, Yi H, Rosenblatt HM, et al. Interleukin-2 receptor -γ chain mutation results in X-linked severe combined immunodeficiency in humans. Cell. 1993;73:147-157.
141. Puck JM, Deschenes SM, Porter JC, et al. The interleukin-2 receptor gamma chain maps to Xq13.1 and is mutated in severe combined immunodeficiency, SCIDX1. Hum Mol Genet. 1993;2: 1099-1104.
142. Johnston JA, Kawamura M, Kirken RA, et al. Phosphorylation and activation of the Jak-3 kinase in response to interleukin-2. Nature. 1994; 370:151-153.
143. Pepper AE, Buckley RH, Small TN, Puck JM. Two mutational hotspots in the interleukin-2 receptor gene causing human X-linked severe combined immunodeficiency. Am J Hum Genet. 1995;57: 564-571.
144. Disanto JP, Muller W, GuyGrand D, Fischer A, Rajewsky K. Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor γc chain. Proc Natl Acad Sci U S A. 1995;92:377-381.
145. Russell SM, Tayebi N, Nakajima H, et al. Mutation of JAK3 in a patient with SCID: essential role of JAK3 in lymphoid development. Science. 1995; 270:797-800.
146. Macchi P, Villa A, Gillani S, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immunodeficiency (SCID). Nature. 1995;377:65-68.
147. Kostmann R. Infantile genetic agranulocytosis. Acta Paediatr. 1956;45(suppl 105):1-78.
148. Kawaguchi Y, Kobayashi M, Tanabe A, et al. Granulopoiesis in patients with congenital neutropenia. Am J Hematol. 1985;20:223-234.
149. Gillio AP, Gabrilove JL. Cytokine treatment of inherited bone marrow failure syndromes. Blood. 1993;81:1669-1674.
150. Kalra R, Dale D, Freedman M, et al. Monosomy 7 and activating RAS mutations accompany malignant transformation in patients with congenital neutropenia. Blood. 1995;86:4579-4586.
151. Dong F, Brynes RK, Tidow N, Welte K, Löwenberg B, Touw IP. Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med. 1995;333:487-493.
152. Dong F, Dale DC, Bonilla MA, et al. Mutations in the granulocyte colony-stimulating factor receptor gene in patients with severe congenital neutrope-nia. Leukemia. 1997;11:120-125.
153. Welte K, Touw IP. G-CSF receptor mutations in patients with severe chronic neutropenia: a step in leukemogenesis [abstract]. Blood. 1997;90: 433a.
154. Hermans MHA, Ward AC, Antonissen C, Karis A, Lowenberg B, Touw IP. Perturbed granulopoiesis in mice with a targeted mutation in the granulocyte colony-stimulating factor receptor gene associated with severe chronic neutropenia. Blood. 1998;92:32-39.
155. Hermans MHA, Antonissen C, Ward AC, Mayen AEM, Ploemacher RE, Touw IP. Sustained receptor activation and hyperproliferation in response to granulocyte colony-stimulating factor (G-CSF) in mice with a severe congenital neutropenia/ acute myeloid leukemia-derived mutation in the G-CSF receptor gene. J Exp Med. 1999;189:683-692.
156. Hunter MG, Avalos BR. Deletion of a critical internalization domain in the G-CSFR in acute myelogenous leukemia preceded by severe congenital neutropenia. Blood. 1999;93:440-446.
157. Rauprich P, Kasper B, Tidow N, Welte K. The protein tyrosine kinase JAK2 is activated in neutrophils from patients with severe congenital neutropenia. Blood. 1995;86:4500-4505.
158. Ward AC, van Aesch YM, Gits J, et al. Novel point mutation in the extracellular domain of the granulocyte colony-stimulating factor (G-CSF) receptor in a case of severe congenital neutropenia hyporesponsive to G-CSF treatment. J Exp Med. 1999;190:497-507.
159. Youssoufian H, Longmore G, Neumann D, Yoshimura A, Lodish HF. Structure, function and activation of the Epo receptor. Blood. 1993;81: 2223-2236.
160. Arcasoy MO, Harris KW, Forget BG. A human erythropoietin receptor gene mutant causing familial erythrocytosis is associated with deregulation of the rates of Jak2 and Stat5 inactivation. Exp Hematol. 1999;27:63-74.
161. De la Chapelle A, Träskelin AL, Juvonen E. Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. Proc Natl Acad Sci U S A. 1993;90:4495-4499.
162. Sokol L, Luhovy M, Guan Y, Prchal JF, Semenza GL, Prchal IT. Primary familial polycythemia: a frameshift mutation in the erythropoietin receptor gene and increased sensitivity of erythroid progenitors to erythropoietin. Blood. 1995;86:15-22.
163. Fanconi G. Familial constitutional panmyelocytopathy, Fanconi's anemia (F.A.), I: clinical aspects. Semin Hematol. 1967;4:233-240.
164. Billardon B, Moustacchi E. Comparison of the sensitivity of Fanconi's anemia and normal fibroblasts of sister-chromatic exchanges by photoaddition of mono- and bi-functional psoralens. Mutat Res. 1986;174:241-246.
165. Whitney MA, Royle G, Low MJ, et al. Germ cell defects and hematopoietic hypersensitivity to γ-interferon in mice with a targeted disruption of the Fanconi anemia C gene. Blood. 1996;88:49-58.
166. Rathbun RK, Faulkner GR, Ostroki MH, et al. Inactivation of the Fanconi anemia group C gene augments interferon-gamma-induced apoptotic responses in hematopoietic cells. Blood. 1997; 90:974-985.
167. Pang Q, Fagerlie S, Christianson TA, Keeble W, Bagby GC. The Fanconi anemia (FA) protein FAC is required for recruitment of Stat1 to the IFNγ receptor complex [abstract]. Blood. 1998;92:476a.
168. Gutterman JU. Cytokine therapeutics: lessons from interferon α. Proc Natl Acad Sci U S A. 1994; 91:1198-1205.
169. Kuzel TM, Roenigk HH, Samuelson E, et al. Effectiveness of interferon alpha-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome. J Clin Oncol. 1995;13:257-263.
170. Sun WH, Pebon C, Alsayed Y, et al. Interferon-α resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. Blood. 1998;91:570-576.
171. Wong LH, Krauer KG, Hatzinisiriou I, et al. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3γ J Biol Chem. 1996;272:28,779-28,785.
172. Sakamoto H, Yasukawa H, Masuhara M, et al. A Janus kinase inhibitor, JAB, is an interferon-γ inducible gene and confers resistance to interferons. Blood. 1998;92:1668-1676.
173. Hoefsloot LH, van Amelsvoort MP, Broeders LC, et al. Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome. Blood. 1997;89:1690-1700.
174. Tabrizi M, Yang W, Jiao H, et al. Reduced Tyk2/ SHP-1 interaction and lack of SHP-1 mutation in a kindred of familial hemophagocytic lymphohistiocytosis. Leukemia. 1998;12:200-206.
175. Taylor N, Uribe L, Smith S, Jahn T, Kohn DB, Weinberg K. Correction of interleukin-2 receptor function in X-SCID lymphoblastoid cells by retrovirally mediated transfer of the gamma-c gene. Blood. 1996;87:3103-3107.
176. Bunting KD, Sangster MY, Ihle JN, Sorrentino BP. Restoration of lymphocyte function in Janus kinase 3-deficient mice by retroviral-mediated gene transfer. Nat Med. 1998;4:58-64.
177. Chen X, Vinkemeier U, Zhao Y, Jeruzalmi D, Darnell JE Jr, Kuriyan J. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell. 1998;93:827-839.
178. Becker S, Groner B, Muller CW. Three-dimensional structure of the Stat3 beta homodimer bound to DNA. Nature. 1998;394:145-151.
179. Kaplan MH, Schindler U, Smiley ST, Grusby MJ. Stat6 is required for mediating responses to IL-4 and for the development of Th2 cells. Immunity. 1996;4:313-319.
180. Kaplan MH, Wurster AL, Grusby MJ. A signal transducer and activator of transcription (Stat)4-independent pathway for the development of T helper type 1 cells. J Exp Med. 1998;188:1191-1196.
181. Mui AL-F, Wakao H, Kinoshita T, Kitamura T, Miyajima A. Suppression of interleukin-3-induced gene expression by a C-terminal truncated Stat5: role of Stat5 in proliferation. EMBO J. 1996;15: 2425-2433.
182. Matsumura I, Ishikawa J, Nakajima K, et al. Thrombopoietin-induced differentiation of a human megakaryoblastic leukemia cell line, CMK, involves transcriptional activation of p21(WAF1/ Cip1) by STAT5. Mol Cell Biol. 1997;17:2933-2943.
183. Matsumura I, Kitamura T, Wakao H, et al. Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells. EMBO J. 1999;18: 1367-1377.
184. Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene. 1996;13:247-254.
185. Chai SK, Nichols GL, Rothman P. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol. 1997; 159:4720-4728.
186. Carlesso N, Frank DA, Griffin JD: Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med. 1996;183:811-820.
187. Frank DA, Varticovski L. BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats. Leukemia. 1996;10:1724-1730.
188. Danial NN, Pernis A, Rothman PB. Jak-STAT signalling induced by the v-abl oncogene. Science. 1995;269:1875-1877.
189. Yu C-L, Jove R, Burakoff SJ. Constitutive activation of the Jak kinase-STAT pathway in T lymphoma overexpressing the lck protein tyrosine kinase. J Immunol. 1997;159:5206-5210.
190. Zhang Q, Nowak I, Vonderheid EC, et al. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci U S A. 1996;93:9148-9153.
191. Nielsen M, Kaktoft K, Nordahl M, et al. Constitutive activation of a slowly migrating isoform of STAT3 in mycosis fungoides: tyrphostin AG490 inhibits STAT3 activation and growth of mycosis fungoides tumor cell lines. Proc Natl Acad Sci U S A. 1997;94:6764-6769.
192. lck. J Virol. 1997;71:6677-6682.
193. Weber-Nordt RM, Egen C, Wehinger J, et al. Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood. 1996;88:809-816.
194. Gouilleux-Gruart B, Gouilleux F, Desaint C, et al. STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood. 1996;87:1692-1697.
195. Hayakawa F, Towatari M, Iida H, et al. Differential constitutive activation between STAT-related proteins and MAP kinase in primary acute myelogenous leukaemia. Br J Haematol. 1998;101:521-528.
196. Xia Z, Baer MR, Block AW, Baumann H, Wetzler M. Expression of signal transducers and activators of transcription proteins in acute myeloid leukemia blasts. Cancer Res. 1998;58:3173-3180.
197. Liu R, Fan C, Garcia R, Jove R, Zuckerman KS Constitutive activation of the JAK/STAT5 signal transduction pathway correlates with growth facfor independence of megakaryocytic leukemic cell lines. Blood. 1999;93:2369-2379.
198. Migone T-S, Lin J-X, Cereseto A, et al. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-1. Science. 1995;269:79-81.
199. Takemoto S, Mulloy JC, Cereseto A, et al. Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/ STAT proteins. Proc Natl Acad Sci U S A. 1997; 94:13,897-13,902.